In vitro and in vivo evaluation of 64Cu-radiolabeled kccysl peptides for targeting epidermal growth factor receptor-2 in breast carcinomas

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 693-703

  Kumar, Senthil R ^a,b   Gallazzi, Fabio A ^c   Ferdani, Riccardo ^d   Anderson, Carolyn J ^d   Quinn, Thomas P ^a   Deutscher, Susan L ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

64Cu chelators; Breast cancer; EGFR 2; peptide; PET imaging

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID(GLYCYLSERYLGLYCYL)LYSYLCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID(GLYCYLSERYLGLYCYL)LYSYLCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE CU 64; 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE 4,11 DIACETIC ACID(GLYCYLSERYLGLYCYL)LYSYLCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG STABILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; RECEPTOR AFFINITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCID MOUSE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMAL STRUCTURES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; COPPER RADIOISOTOPES; DRUG STABILITY; EPITHELIAL CELLS; FEMALE; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KIDNEY; MICE; MICE, SCID; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION;

EID: 78651274373     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0820     Document Type: Article

References (47)

1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203.
2. Hung MC, Lau YK. Basic science of HER2/neu: A review. Semin Oncol 1999;26 (Suppl):51.
3. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the Her2/neuproto-oncogene in normal human and adult and fetal tissues. Oncogene 1990;5:53.
4. Ross J, Fletcher JA. The Her2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413.
5. Hynes NE, Stern DF. The biology of ErbB-2/neu/Her-2 and its role in cancer. Biochimica et Biophysica Acta 1994;1198:165.
6. Holbro T, Hynes NE. ErbB receptors: Directing key signaling networks throughout life. Ann Rev of Pharmacol Toxicol 2004;44:195.
7. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol1989;9:1165.
8. Harwerth IM, Wels W, Schlegel J, et al. Monoclonal anti-bodies directed to the ErbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68:1140.
9. Houimel M, Schneider P, Terskikh A, et al. Selection of pep-tides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer 2001; 92:748.
10. Li X, Stuckert P, Bosch I, et al. Single-chain antibody-medi-ated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001;8:555.
11. Karasseva NG, Glinsky VV, Chen NX, et al. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 2002;21:287.
12. Nilsson F, Tarli L, Viti F, et al. The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 2000;43:165.
13. Pero SC, Shukla GS, Armstrong AL, et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer 2004;111:951.
14. Blok D, Feitsma RI, Vermeij P, et al. Peptide radiopharma-ceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511.
15. Signore A, Annovazzi A, Chianelli M, et al. Peptide radio-pharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555.
16. Reubi JC, Maecke HR. Peptide-based probes for cancer im-aging. J Nucl Med 2008;49:1735.
17. Wadas TJ, Anderson CJ. Radiolabeling of TETA-and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 2006; 1:3062.
18. 111In- radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin Cancer Res 2007;13:6070.
19. Wadas TJ, Wong EH, Weisman GR, et al. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007;13:3.
20. Bearn AG, Kunkel HG. Localization of Cu64 in serum frac-tions following oral administration: An alteration in Wilson's disease. Proc Soc Exp Biol Med 1954;85:44.
21. Owen CA Jr., Hazelrig JB. Metabolism of cu-64-labeled copper by the isolated rat liver. Am J Physiol 1966;210: 1059.
22. Jones-Wilson TM, Deal KA, Anderson CJ, et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 1998;25:523.
23. 67Cu chelates: Comparison with 111In and 57Co. Int J Rad Appl Instrum B 1986;13:363.
24. Smith SV. Molecular imaging with copper-64. J Inorg Bio-chem 2004;98:1874.
25. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conven-tional tetraazamacrocyclic complexes. J Med Chem 2004; 47:1465.
26. Sun X, Wuest M, Weisman GR, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002;45:469.
27. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 2007;104:12462.
28. Wu Y, Zhang X, Xiong Z, et al. MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707.
29. Studer M, Meares CF. Synthesis of novel 1,4,7-triazacyclo-nonane-N,N', N"-triacetic acid derivatives suitable for pro-tein labeling. Bioconjug Chem 1992;3:337.
30. Brechbiel MW, McMurry TJ, Gansow OA. A direct synthesis of bifunctional chelating agent for radiolabeling protein. Tetrahedron Lett 1993;34:3691.
31. Sprague JE, Peng Y, Sun X, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004; 10:8674.
32. Tommasi S, Fedele V, Lacalamita R, et al. Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett 2004;209:215.
33. Vegt E, van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008;49:1506.
34. Houimel M, Schneider P, Terskikh A, et al. Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer 2001; 92:748.
35. Urbanelli L, Ronchini C, Fontana L, et al. Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. J Mol Biol 2001;313:965.
36. Price JE, Zhang FA, Radinsky RD, et al. Characterization of variants of a human breast cancer cell line isolated from metastases in different organs of nude mice. Int J Oncol 1994;5:459.
37. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004;21:543.
38. Chambers AF. MDA-MB-435 and M14 cell lines: Identical but not M14 melanoma? Cancer Res 2009;69:5292.
39. Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9.
40. Bass LA, Wang M, Welch MJ, et al. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000;11:527.
41. Moi MK, Meares CF, McCall MJ, et al. Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985;148:249.
42. Liu Z, Yan Y, Liu S, et al. 18F, 64Cu, and 68Ga lableled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009;20:1016.
43. 2+ and variance of metallothionein during tumor treatment by copper. Nucl Med Biol 1998;25:111.
44. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2002;27:273.
45. Wadas TJ, Eiblmaier M, Zheleznyak A, et al. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 2008;49:1819.
46. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276.
47. 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007;48:64.